Actinium Pharmaceuticals, Inc. submitted a compliance plan to NYSE American on June 18, 2026, to address non-compliance with stockholders' equity requirements. The company was notified on May 27, 2026, that it failed to maintain the minimum $4.0 million stockholders' equity threshold required by the exchange. Actinium Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing radiopharmaceuticals for cancer treatment.
